Sentences with phrase «with approval for»

Directed key operations generating $ 800M in yearly sales, with approval for transfers to $ 11M daily.

Judge applicants begin with approval for only the breeds they have bred.

In contrast with their approvals for corporate cards, credit card issuers do not consider the finances of your business when you apply for a business credit card, which makes them a popular choice for startups.

In contrast with their approvals for corporate cards, credit card issuers do not consider the finances of your business when you apply for a business credit card, which makes them a popular choice for startups.

Because these policies provide coverage for a set period of time rather than your entire life, the insurance companies tend to be more lenient with approvals for applicants that are «high - risk.»

Not exact matches

The approval time for products with health claims can be as along as three years in Canada, much slower than the FOSHU regulatory system in Japan or similar setups in Europe.

Compared with standard commercial loan products, the underwriting examines cash flow closely as a basis for approvals and decisions on loan rates.

DELTA TOWNSHIP, Mich. — Michigan regulators on Friday cleared DTE Energy's request to build a near - $ 1 billion natural gas power plant, the first approval of such a large facility for a regulated utility in decades and a move that coincides with the retirement of coal - fired plants.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The company was subject to much speculation that it might tie up with larger peer Verizon, but Charter instead partnered with Comcast on an expansive wireless services agreement that requires one to seek the other's approval for a major transaction with a wireless company.

Work will start on a game - changing redevelopment of Forrest Chase in coming months, with fund manager ISPT expected to receive planning approval for a major revamp of the CBD mall later this week.The

The move to preemptively brand «property scalpers» a problem, however, smacks of an effort to create a villain that the government can then vanquish — a useful tactic for a government headed by a leader with a record - low approval rating facing an election next year.

The Food and Drug Administration (FDA) under Commissioner Scott Gottlieb is continuing its quest to ramp up generic drug approvals, this time for complex generics that could compete with products such as Mylan's EpiPen.

At a Wells Fargo media and telecom conference on Wednesday morning, AT&T chief financial officer John Stephens said that closing the mega-deal for Time Warner «is now uncertain» even as he declined to elaborate on the company's ongoing discussions with the U.S. Department of Justice about securing regulatory approval for the transaction.

Sarepta Therapeutics, which won a pioneering Food and Drug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatments.

The SEC filing specified that «if Mr. Spiegel's or Mr. Murphy's employment with us is terminated, they will continue to have the ability to exercise the same significant voting power and potentially control the outcome of all matters submitted to our stockholders for approval.»

But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to slash the regulatory period for a different experimental specialty treatment being developed by a drug maker or, more often, sold for potentially hundreds of millions of dollars to another pharma company.

But this summer, Spanish officials granted approval for a product made with artificially frozen grapes to be labelled as «icewine.»

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Even with the Freeport terminal approval, it seems, there's room for Canada.

The service is opened up to individuals for tinkering, with edits having to pass through an approval process before they are accepted into Google Maps and Google Earth.

21st Century Fox is currently trying to gain regulatory approval in the UK for a merger with Sky, both of which are owned by billionaire Rupert Murdoch.

The September decision by the Obama administration to delay final approval for the Dakota Access Pipeline was intended to give federal officials more time to consult with Native American tribes that have faced dispossession from lands for decades.

Factors which could cause actual results to differ materially from these forward - looking statements include such factors as the Company's ability to accomplish its business initiatives, obtain regulatory approval and protect its intellectual property; significant fluctuations in marketing expenses and ability to achieve or grow revenue, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission.

Yet there is another scenario, which, many observers believe, is just as likely: that Putin, with about $ 465 billion in foreign cash and gold in Russia's Central Bank, could try to ride out sanctions, perhaps for years, and emerge even stronger (his approval ratings are above 80 %) as the Man Who Faced Down the West.

Republican Senator John Hoeven of North Dakota, who co-sponsored the Keystone bill with Landrieu, has pledged to keep trying to force approval of the project that the administration has kept under review for more than six years.

ORIGINAL REQUEST: For any account / wallet / vault with respect to which the registered user gave any third party access, control, or transaction approval authority, all powers of attorney, letters of wishes, corporate minutes, or other agreements or instructions granting the third party such access, control, or approval authority.

Audi just showed off its new 2019 A8, the first vehicle for market with Level 3 autonomy, and the automaker still needs to get approval from regulators around the world to enable the system for use on public roads.

Adam Fisher, head of macro investing for Soros Fund Management, received the approval, but he has yet to make any bets on cryptocurrencies, Bloomberg said, citing people familiar with the matter.

In an interview with Canadian Business deputy editor James Cowan, Odum spoke about whether the Keystone XL pipeline will ever receive U.S. approval, why cap - and - trade is good for industry, and what it will take for Canada to become a world leader in LNG.

Liberty Resources is ticking the remaining boxes on its list of requirements to be met for its proposed acquisition of Cirrus Networks, with an independent expert giving the transaction its stamp of approval today, ahead of a shareholders meeting next month.

TPG Telecom has lifted its stake in Amcom Telecommunications to 19.9 per cent, making it harder for Amcom to win approval at next week's shareholder meeting for its planned merger with Vocus Communications.

Getting the external stamp of approval was, for Keller, a way of encouraging others to consider the standard, with the long - term goal of developing a sustainable - business cluster that would help drive the West Michigan economy.

With positive reviews, the breathable shelters with a translucent fabric roof, perfect for the suffocating humidity of the Amazon, won approval, and Weatherhaven finally began sellWith positive reviews, the breathable shelters with a translucent fabric roof, perfect for the suffocating humidity of the Amazon, won approval, and Weatherhaven finally began sellwith a translucent fabric roof, perfect for the suffocating humidity of the Amazon, won approval, and Weatherhaven finally began selling.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

BRUSSELS, April 18 - EU antitrust regulators are set to hit French telecoms and cable group Altice with a hefty fine for concluding its 2015 acquisition of PT Portugal without first waiting for official approval, a person familiar with the matter said on Wednesday.

AT&T CEO Randall Stephenson insisted the company was not told it had to sell CNN in order to get approval for its merger with Time Warner.

Qualcomm, which plans to fund the additional $ 6 billion with cash on hand and new debt, said approval from China's Ministry of Commerce is the only regulatory nod remaining for the closure of the NXP deal.

He got back to me right away with a fun reply and the approval I asked for.

That led to an earlier Food and Drug Administration (FDA) approval for Keytruda than Opdivo in 2014 since the former was a more targeted therapy; but it also left Merck with a smaller slice of the market.

He suggested coming up with a faster approval timeline for generics coming to market to take on drugs with high prices.

The company won U.S. court approval on Tuesday for its multi-billion dollar debt restructuring plan after reaching a deal with more than 40 banks, unsecured creditors and shipyards.

The approval (with some conditions) was the last big hurdle for the deal, which has been in the works since May 2016.

For our most valuable tech types and top management, we had an «evergreen» plan: With board approval, we kept providing additional options.

We're working with some state governments to get some quick approvals for rebates for our commercial customers.

Bayer also said it had filed a request for approval of its planned $ 66 billion takeover of U.S. seeds company Monsanto with EU regulators, according to a Reuters report.

The CEO of Publicis Groupe revealed that the approval process for its proposed merger with Omnicom is progressing faster than expected.

The company is working now to gain approval for the pilot program with hopes of eventually expanding the number of taxis involved to the thousands.

And there have been developments in cellular therapies to treat cancer, with two treatments aiming for approval by the end of 2017.